CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals recently presented promising data from their phase 1a/1b study of CS5001, an innovative antibody-drug conjugate targeting ROR1, at the ASCO 2024 meeting. The drug demonstrated encouraging anti-tumor activity and was well-tolerated in heavily pretreated patients with advanced solid tumors and lymphomas. Plans are underway to continue dose-escalation trials and potentially begin registrational trials by the end of 2024.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.
